{
    "clinical_study": {
        "@rank": "104150", 
        "arm_group": {
            "arm_group_label": "CELYVIR", 
            "arm_group_type": "Experimental", 
            "description": "Patients will received weekly (n=6) IV infusion of Celyvir."
        }, 
        "brief_summary": {
            "textblock": "The investigators will evaluate the safety of weekly infusions (n=6) of CELYVIR in children\n      and adults with metastatic and refractory solid tumors. CELYVIR consists in bone\n      marrow-derived autologous mesenchymal stem cells (MSCs) infected with ICOVIR5, an oncolytic\n      adenovirus. In addition to data on toxicities the investigators will evaluate clinical\n      response."
        }, 
        "brief_title": "Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Children", 
            "Solid Tumors", 
            "Metastases"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasm Metastasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children: Up to 18 yrs. Refractory to at least 2 previous therapy lines. Life\n             expectancy more than 6 months. Measurable disease.\n\n          -  Adults: 18-75 yrs. Refractory to at least 2 previous therapy lines. ECOG (Eastern\n             Cooperative Oncology Group) <2. Measurable disease.\n\n        Exclusion Criteria:\n\n          -  Pregnancy.\n\n          -  Central Nervous System metastasis.\n\n          -  Experimental therapy during the previous month.\n\n          -  Chemotherapy less than 3 weeks previous.\n\n          -  Any organ functionally impaired.\n\n          -  Concurrent infectious disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844661", 
            "org_study_id": "EudraCT2008-000364-16"
        }, 
        "intervention": {
            "arm_group_label": "CELYVIR", 
            "intervention_name": "CELYVIR", 
            "intervention_type": "Biological", 
            "other_name": "Bone marrow-derived autologous mesenchymal stem cells infected with ICOVIR5, an oncolytic adenovirus."
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mesenchymal stem cells", 
            "Oncolytic adenovirus"
        ], 
        "lastchanged_date": "May 1, 2013", 
        "location": {
            "contact": {
                "email": "mramirezo.hnjs@salud.madrid.org", 
                "last_name": "Manuel Ramirez, MD PhD", 
                "phone": "+34915035938"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28009"
                }, 
                "name": "Hospital Universitario Ni\u00f1o Jes\u00fas"
            }, 
            "investigator": {
                "last_name": "Manuel Ramirez, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors.", 
        "overall_contact": {
            "email": "mramirezo.hnjs@salud.madrid.org", 
            "last_name": "Manuel Ramirez, MD PhD", 
            "phone": "+34915035938"
        }, 
        "overall_official": {
            "affiliation": "Hospital Universitario Ni\u00f1o Jes\u00fas", 
            "last_name": "Manuel Ram\u00edrez, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency for Medicine and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will record any sign or symptom that could be related to the infusion of Celyvir.", 
            "measure": "Adverse effects after intravenous infusions", 
            "safety_issue": "Yes", 
            "time_frame": "48 hours after each infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844661"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain", 
            "investigator_full_name": "Manuel Ram\u00edrez, MD PhD", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Clinical outcome will be labelled as complete response, partial response, stable disease or disease progression.", 
            "measure": "Clinical outcome", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 months after the last infusion"
        }, 
        "source": "Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain", 
        "sponsors": {
            "collaborator": {
                "agency": "Instituto de Salud Carlos III", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}